[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercholerolemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercholerolemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,69,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100652322","cardiovascular-kidney-metabolic-ckm-guided-therapy-for-patients-after-acute-coronary-syndrome-100652322",false,"NCT07773272","Cardiovascular-kidney-metabolic (CKM)-Guided Therapy for Patients After Acute Coronary Syndrome","SLIM-3","Inclusion Criteria:\n\n* Age \\> 18 years\n* Hospitalised with acute coronary syndrome\n* Underwent percutaneous coronary intervention\n\nExclusion Criteria:\n\n* Acute coronary syndrome secondary to other diseases\n* Life expectancy \\\u003C 1 year based on the clinician's expertise","ALL","18 Years",{"count":19,"type":20},1215,"ESTIMATED","2 Years","OBSERVATIONAL","Patients with a history of myocardial infarction are at significantly increased risk of recurrent cardiovascular events. Despite established clinical guidelines, secondary preventive care is often initiated too late, inadequate in intensity or incomplete in application. As a result, important opportunities to prevent serious outcomes are missed.\n\nThe aim of this project is to investigate whether rapid, guideline-based treatment following myocardial infarction leads to improved patient outcomes. The study protocol is based on current clinical guidelines and targets key domains including diabetes, hypertension, and hypercholesterolemia. Outcomes of patients treated according to the study protocol will be compared to those receiving standard care. Primary endpoints include major adverse cardiac- and cerebrovascular events within a 24-month follow-up period.\n\nThe investigators hypothesize that rapid, guideline-based intervention will result in improved risk factor management, leading to a reduction in cardiovascular events and mortality. For patients, this may translate into improved health, quality of life and life expectancy. This project aims to deliver a practical protocol for effective secondary prevention in clinical practice, which is expected to reduce healthcare utilization in the long term. With this initiative, the investigators seek to take a significant step toward improving post-myocardial infarction care and contributing to sustainable cardiovascular healthcare.",[25,26,27,28,29],"Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)","Hypercholerolemia","Hypertension","Diabete Mellitus","Cardiovascular Risk Management","RECRUITING","2026-08-18",{"date":33,"type":34},"2026-08-19","ACTUAL",{"date":36,"type":34},"2026-03-16",{"date":38,"type":20},"2029-03-31",{"name":40,"class":41},"Zuyderland Medisch Centrum","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100649963","effects-of-statins-and-hormone-replacement-therapy-in-coagulation-profile-of-menopausal-women-with-dyslipidemia-100649963","NCT07742488","Effects of Statins and Hormone Replacement Therapy in Coagulation Profile of Menopausal Women With Dyslipidemia","The Role of STAtins in Reversing Coagulation Profile Changes Induced by Hormone Replacement Therapy in Menopausal Women With Hypercholesterolemia: the STAR-HRT Study","STAR-HRT","Inclusion Criteria:\n\n* Women aged between 45 and 55\n* Early postmenopausal period (within 5 years of the last menstrual cycle).\n* Prescription of oral estrogen-progestin HRT for symptoms that require it according to current guidelines\n* Low-moderate cardiovascular risk (SCORE2 calculation and assessment based on age)\n* LDL levels above target according to the class of risk\n\nExclusion Criteria:\n\n* Recent pregnancy (\\\u003C1 year) or current breastfeeding\n* Ongoing therapies that interfere with the study objectives: HRT or other estroprogestin therapy, lipid-lowering drugs, anticoagulants, or antiplatelet agents\n* Current or previous venous or arterial thrombotic event\n* Diagnosis of cancer for which treatment is ongoing or has been discontinued for less than 10 years\n* Known hereditary thrombophilia\n* Chronic inflammatory bowel disease\n* Diabetes mellitus\n* Body mass index (BMI) \\> 30 kg\u002Fm²\n* Acute\u002Fchronic liver failure or abnormal liver enzymes (ALT or AST \\> 100 IU\u002FL; GGT \\> 100 IU\u002FL; alkaline phosphatase \\> 250 IU\u002FL)\n* Other known risk factors for VTE or contraindications to HRT\n* Refusal to take HRT","FEMALE","45 Years","55 Years",{"count":55,"type":20},70,"The goal of this study is to understand whether statin therapy, a common lipid-lowering therapy, may improve the coagulation profile of menopausal women with hypercholesterolemia undergoing hormone replacement therapy with oral estroprogestin. It will also learn about the liver safety of the combination. The main questions will be:\n\n1. does hormone replacement therapy affect the coagulation profile?\n2. when we add statin therapy due to hypercholesterolemia not improving with lifestyle, does it reverse eventual changes of the coagulation profile occurred after initiation of hormone replacement therapy?\n3. do the two therapies have an effect on overall inflammation of the organism?\n\nParticipants will be asked to participate to the study before starting any therapy, if they need hormone relacement therapy due to symptoms, if they have a new onset of dyslipidemia and if they do not have contraindications to the therapies object of the study. The study is observational, thus it will not affect in any way the clinical care, which will follow only guidelines. During routine blood sample collection, additional aliquotes will be taken for the study at the recruitment, after 3 months of hormone replacement therapy and lifestyle changes, at the end of the study (after one year from the recruitment).",[58,26,59],"Menopausal Complaints","Coagulation Tests","2026-07-28",{"date":62,"type":34},"2026-08-03",{"date":64,"type":34},"2025-10-15",{"date":66,"type":20},"2029-12",{"name":68,"class":41},"University of Pisa",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":79,"studyType":22,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100644912","faisalabad-initiative-of-research-and-management-of-ncds-100644912","NCT07676214","Faisalabad Initiative of Research and Management of NCDs","FIRM-NCD","Inclusion Criteria:\n\nAge: 18 years and above Gender: Both male and female Permanent residents of the selected study areas Willing to participate and provide informed consent\n\nExclusion Criteria:\n\nPregnant and lactating women Oral and injectable contraceptive users Individuals with severe physical or cognitive impairments that prevent them from providing informed consent or participating in the screening procedures Individuals with implanted electronic medical devices (e.g., pacemakers or implantable cardioverter-defibrillators) will not undergo bioelectrical impedance analysis (BIA) for body composition assessment.",true,{"count":78,"type":20},3000,"3 Months","The burden of noncommunicable diseases (NCDs) continues to rise globally, and they have become the leading cause of morbidity and mortality, accounting for over 70% of deaths worldwide¹. Rapid lifestyle transitions and increasing urbanization have disproportionately affected low- and middle-income countries, which now bear a substantial share of the global NCD burden.\n\nPakistan, with a population of 241.5 million, is experiencing a double burden of both communicable diseases and NCDs¹³. The widespread adoption of sedentary lifestyles and unhealthy dietary patterns has contributed to a marked increase in NCDs across the country².\n\nAccording to the WHO Hypertension profile 2025, it is the most prevalent NCD in Pakistan, affecting approximately 42% (41% males and 44% females) of the population¹¹, followed by diabetes, with a reported prevalence of 30.8%¹². Additionally, a recent cross-sectional study among adults attending a tertiary care hospital in Islamabad reported dyslipidemia in 71.6% of men and 78.4% of women, indicating a substantial underlying community burden³. Pakistan also ranks tenth among 188 countries in terms of overweight and obesity prevalence, with nearly half of its population classified as overweight or obese⁴. According to World Health Organization data, 58.1% of Pakistanis are overweight, and 43.9% fall within the obese category⁴.\n\nDespite their profound public health and economic implications, efforts to address NCDs remain fragmented and insufficient.17 There remains a significant research gap in community-based NCD screening initiatives, particularly within the suburban and peri-urban communities of Faisalabad creating an unmet need to initiate a preventive strategy at community level to raise awareness about these diseases. This direction will minimize the increasing incidence and prevalence of NCDs and will ensure the quality health outcomes for better future.\n\nTimely identification of these diseases through screening is a critical step in reducing their impact on individuals and societies. Early detection enables cost-effective management, improved patient outcomes and a higher quality of life.14 One of the most important ways of reducing deaths from noncommunicable diseases (NCDs) is to control the risk factors that lead to their development.6 In this context, the present study aims to evaluate a community-based project focusing on disease awareness, screening, and structured referral to trained treating physicians for early diagnosis and management of major NCDs. The findings are expected to inform scalable, evidence-based interventions to reduce NCD burden and improve population health outcomes in Pakistan.",[28,27,26,82],"Obesity (Disorder)",[84,85,27,86,87],"community screening","Diabetes","Obesity","Hypercholestrolemia","NOT_YET_RECRUITING","2026-06-24",{"date":91,"type":34},"2026-06-30",{"date":93,"type":20},"2026-08-01",{"date":95,"type":20},"2027-12-31",{"name":97,"class":98},"Getz Pharma","INDUSTRY",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":76,"sex":16,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100638182","phase-1-bioequivalence-study-of-aju-c715-and-c715r-in-healthy-adult-volunteers-100638182","NCT07581028","Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers","An Open-Label, Randomized, Fasting, Single-Dose, Two-Sequence, Two-Period Crossover Study to Evaluate the Bioequivalence of \"AJU-C715\" and \"C715R\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n1. Healthy adults aged 19 to less than 60 years at the time of screening\n2. Weight ≥ 50 kg for men or ≥ 45 kg for women, with a calculated body mass index(BMI) of 18 to 30 kg\u002Fm² at the time of screening.\n3. Those who have no congenital chronic disease or chronic disease requiring treatment and who have no pathological symptoms or findings.\n4. Those who are eligible for the clinical trial based on laboratory test results(hematology, blood chemistry, serum, and urine tests) and 12-lead ECG findings during screening.\n5. Those who voluntarily decide to participate and agree to comply with the cautions after hearing and fully understanding the detailed description of this clinical trial.\n6. Those who agree to use highly effective methods of contraception(excluding hormonal methods) to prevent pregnancy, either for themselves or their spouse\u002Fpartner, from the first administration of the investigational medicinal product until one week after the last administration, and who agree not to donate sperm or eggs during this period.\n\nExclusion Criteria:\n\n1. Those who take barbiturate and related (causing induction or inhibition of metabolism) drug within 1 month or the first administration of clinical trial drug within 10 days.\n2. Those who received investigational product or bioequivalence test drug within 6 months before the first administration of clinical trial drug. 3. Those who donated whole blood within 8 weeks, received apheresis within 2 weeks, blood transfusion within 1 month or can't refrain from donating blood from the time of written consent until the end of the study.\n\n4\\. Those who has a history of gastrointestinal disease or surgery which may affect the absorption of the drug.\n\n5\\. Those who exceeding an alcohol consumption criteria Alcohol: Men - 21 glass\u002Fweek, Women - 14 glass\u002Fweek (1 glass: Soju 50 mL, Beer 250mL or liquor: 30mL), Smoke: 20 cigarettes\u002Fday.\n\n6\\. Those who has under\n\n* Those who are hypersensitive to component of the Investigational product and have the medical history\n* Those with active liver disease or persistent elevation of aminotransferase levels of unknown\n* Those taking cyclosporin\n* Those with Myopathy\n* Those with severe Renal Impairment due to Renal Failure\n* Those who has Genetic problems such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption 7. Those who has a history of mental illness. 8. Those who are deemed unfit by the investigators to participate in the clinical trial for other reasons.\n\n  9\\. Women who are pregnant or who may be pregnant and breastfeed.","19 Years","59 Years",{"count":109,"type":20},60,"INTERVENTIONAL",[112],"PHASE1","To Evaluate the Safety and Pharmacokinetics of \"AJU-C715\" and \"C715R\" in Healthy Adults.",[26,115],"Dyslipidemia","2026-05-06",{"date":118,"type":34},"2026-05-12",{"date":120,"type":20},"2026-08-07",{"date":122,"type":20},"2026-08-24",{"name":124,"class":98},"AJU Pharm Co., Ltd."]